News

On average 50 percent of Hodgkin lymphoma patients relapse after ASCT and those patients with additional risk factors can be at even higher risk of relapse. ADCETRIS after

This follows Kitov’s announcement in December 2015, that KIT-302’s pivotal Phase III trial successfully met its primary efficacy endpoint. Kitov CEO Isaac Israel said: "We are fortunate to

Teduglutide is an analogue of human glucagon like peptide 2 (GLP-2) that enhances key structural and functional adaptations in the intestinal mucosa. The European Commission (EC) will now

Children born with ADA-SCID do not have a fully functioning immune system and are unable to fight off common infections. The disease affects nearly 15 children a year

The study compared Faslodex 500mg (fulvestrant) to Arimidex 1mg (anastrozole) to treat locally-advanced or metastatic breast cancer, in post-menopausal women who have not had prior hormonal treatment for

Zinbryta is a humanized IgG1 monoclonal antibody that selectively binds to the high-affinity interleukin-2 (IL-2) receptor subunit (CD25), a protein that is over-expressed on T cells that become

The Probuphine subdermal implant, which utilizes Titan’s proprietary ProNeura technology, delivers buprenorphine continuously for up to six months. The product is expected to be commercially available this summer

B-cell cloning represents a pivotal expansion of the company’s MPS Discovery Engine® platform for isolating monoclonal antibodies against membrane protein targets. Combined with the company’s proprietary Lipoparticle technology

SYM-1219 is a potent, next-generation 5-nitroimidazole antibiotic intended for single-dose oral treatment of BV. Symbiomix also announced a successful meeting with the US Food & Drug Administration (FDA)